Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00205478|
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : December 7, 2007
|Condition or disease||Intervention/treatment||Phase|
|Rheumatoid Arthritis||Drug: VX-702||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo Controlled Study of Two Doses of VX-702 in Subjects With Moderate to Severe Rheumatoid Arthritis|
|Study Start Date :||June 2005|
|Actual Study Completion Date :||February 2006|
- The primary endpoint for the study is the ACR20 response at Week 12.
- The ACR50 and ACR70 responses at 12 weeks will also be assessed as well as other measures.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00205478
Show 43 Study Locations
|Study Director:||Robert Kauffman, MD, PhD||Vertex Pharmaceuticals Incorporated|